Published November 2016 • Catalog no. SDF922K • Price US $3,850
The generic solid dosage form drug segment is a rapidly evolving and highly unpredictable environment that has been a challenge to decision makers attempting to map strategies for success in this segment. There are 597 distinct APIs for which there is at least one approved generic solid dosage form ANDA. These 597 APIs account for 4,229 approved ANDAs. Including all approved doses, the current universe of generic solid dosage forms consists of 9,687 unique tablet and capsule products. These products are marketed and supplied by more than 800 companies. Competition among the various drug and therapeutic classes is uneven, with the top ten segments accounting for a disproportionate level of activity and revenue. Understanding the underlying factors affecting business performance is key to attaining financial targets.
Generic Solid Dosage Forms Report Brochure (Download PDF)
Generic Solid Dosage Forms Report Order Form (Download PDF)
Generic Solid Dosage Forms – What You Will Learn
• Provides detailed analysis of generic drugs supplied as solid dosage forms and assesses key market segments, market dynamics and potential product opportunities
• Presents the competitive picture for generic tablets and capsules in two dozen drug classes
• Evaluates the importance of ANDA filing strategies and indirect ANDA acquisition on participant growth prospects
• Analyzes the impact of patents, exclusivity and litigation on participant market sector prospects
• Assesses the market presence and product position of the top twenty-four generic suppliers in the solid dosage form segment
• Evaluates the impact of economic, technology, and regulatory factors
Generic Solid Dosage Forms – Summary of Contents
Executive Summary
The Market Opportunity
The Economics of Generic Drugs
Growth in Generics
Demand Drivers
Competitive Landscape
Generic Solid Dosage Forms – Growth Factors
Patents and Exclusivity
Litigation and First-to-File ANDA Strategies
Buying and Selling ANDAs
Generic SDFs – Product Considerations
Formulation Factors
Modified Release
Extended Release
Delayed Release
Specialty Dosage Forms
Chewable Tablets
Dissolvable Dosage Forms
Generic Solid Dosage Forms – Market Analysis
Therapeutic Class Analysis
Addiction
Anti-Infective
Antispasmodic
Antiviral
Cardiology
Dermatology
Endocrinology
Gastroenterology
Immunology
Infectious Disease
Metabolic Nephrology
Neurology
NSAIDs
Oncology
Ophthalmology
Osteoporosis
Inhibitors
Pain Management
Reproductive Health
Upper Airway Diseases
Urology
Drug Classes
Includes more than eighty drug classes
Indications
Analyzes more than three dozen market segments
Market Factors
Regulatory Issues
Litigation Issues
Evolving ANDA Filing Strategies
The Role of CMOs
Healthcare Economics
Company Analysis